vs
CNO Financial Group, Inc.（CNO）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是CNO Financial Group, Inc.的1.2倍（$1.4B vs $1.1B），瑞思迈净利率更高（27.6% vs 8.8%，领先18.8%），瑞思迈同比增速更快（11.0% vs 4.2%），过去两年瑞思迈的营收复合增速更高（9.0% vs -0.6%）
CNO金融集团是总部位于美国印第安纳州卡梅尔的金融服务控股公司，前身为康塞科公司。集团旗下保险子公司为美国超400万客户提供人寿保险、年金和补充健康保险产品，通过独立代理人、专属代理人，以及电视广告、直邮等直销触达用户。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
CNO vs RMD — 直观对比
营收规模更大
RMD
是对方的1.2倍
$1.1B
营收增速更快
RMD
高出6.8%
4.2%
净利率更高
RMD
高出18.8%
8.8%
两年增速更快
RMD
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.4B |
| 净利润 | $100.7M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | 15.2% | 34.6% |
| 净利率 | 8.8% | 27.6% |
| 营收同比 | 4.2% | 11.0% |
| 净利润同比 | -39.4% | 13.9% |
| 每股收益（稀释后） | $1.02 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNORMD
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | $1.2B | ||
| Q1 24 | $1.2B | $1.2B |
净利润CNORMD
| Q4 25 | $100.7M | $392.6M | ||
| Q3 25 | $23.1M | $348.5M | ||
| Q2 25 | $91.8M | $379.7M | ||
| Q1 25 | $13.7M | $365.0M | ||
| Q4 24 | $166.1M | $344.6M | ||
| Q3 24 | $9.3M | $311.4M | ||
| Q2 24 | $116.3M | $292.2M | ||
| Q1 24 | $112.3M | $300.5M |
毛利率CNORMD
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | — | 58.6% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 57.9% |
营业利润率CNORMD
| Q4 25 | 15.2% | 34.6% | ||
| Q3 25 | 13.7% | 33.4% | ||
| Q2 25 | 9.8% | 33.7% | ||
| Q1 25 | 10.4% | 33.0% | ||
| Q4 24 | 15.8% | 32.5% | ||
| Q3 24 | 13.6% | 31.6% | ||
| Q2 24 | 13.9% | 31.2% | ||
| Q1 24 | 6.5% | 31.3% |
净利率CNORMD
| Q4 25 | 8.8% | 27.6% | ||
| Q3 25 | 1.9% | 26.1% | ||
| Q2 25 | 8.0% | 28.2% | ||
| Q1 25 | 1.4% | 28.3% | ||
| Q4 24 | 15.1% | 26.9% | ||
| Q3 24 | 0.8% | 25.4% | ||
| Q2 24 | 10.9% | 23.9% | ||
| Q1 24 | 9.7% | 25.1% |
每股收益（稀释后）CNORMD
| Q4 25 | $1.02 | $2.68 | ||
| Q3 25 | $0.24 | $2.37 | ||
| Q2 25 | $0.91 | $2.58 | ||
| Q1 25 | $0.13 | $2.48 | ||
| Q4 24 | $1.58 | $2.34 | ||
| Q3 24 | $0.09 | $2.11 | ||
| Q2 24 | $1.06 | $1.97 | ||
| Q1 24 | $1.01 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.4B |
| 总债务越低越好 | — | $403.9M |
| 股东权益账面价值 | $2.6B | $6.3B |
| 总资产 | $38.8B | $8.5B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资CNORMD
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $932.7M | ||
| Q4 24 | — | $521.9M | ||
| Q3 24 | — | $426.4M | ||
| Q2 24 | — | $238.4M | ||
| Q1 24 | — | $237.9M |
总债务CNORMD
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | — | $662.9M | ||
| Q3 24 | — | $667.6M | ||
| Q2 24 | — | $697.3M | ||
| Q1 24 | — | $997.0M |
股东权益CNORMD
| Q4 25 | $2.6B | $6.3B | ||
| Q3 25 | $2.6B | $6.1B | ||
| Q2 25 | $2.5B | $6.0B | ||
| Q1 25 | $2.5B | $5.5B | ||
| Q4 24 | $2.5B | $5.3B | ||
| Q3 24 | $2.7B | $5.2B | ||
| Q2 24 | $2.4B | $4.9B | ||
| Q1 24 | $2.4B | $4.6B |
总资产CNORMD
| Q4 25 | $38.8B | $8.5B | ||
| Q3 25 | $38.3B | $8.3B | ||
| Q2 25 | $37.3B | $8.2B | ||
| Q1 25 | $37.4B | $7.6B | ||
| Q4 24 | $37.9B | $7.1B | ||
| Q3 24 | $37.6B | $7.2B | ||
| Q2 24 | $36.3B | $6.9B | ||
| Q1 24 | $34.9B | $6.8B |
负债/权益比CNORMD
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $195.7M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | — | $311.2M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | 1.94× | 0.87× |
| 过去12个月自由现金流最近4个季度 | — | $1.8B |
8季度趋势，按日历期对齐
经营现金流CNORMD
| Q4 25 | $195.7M | $339.7M | ||
| Q3 25 | $197.8M | $457.3M | ||
| Q2 25 | $145.5M | $538.8M | ||
| Q1 25 | $136.7M | $578.7M | ||
| Q4 24 | $191.0M | $308.6M | ||
| Q3 24 | $231.2M | $325.5M | ||
| Q2 24 | $110.9M | $440.1M | ||
| Q1 24 | $94.6M | $402.0M |
自由现金流CNORMD
| Q4 25 | — | $311.2M | ||
| Q3 25 | — | $414.4M | ||
| Q2 25 | — | $508.2M | ||
| Q1 25 | — | $557.9M | ||
| Q4 24 | — | $288.0M | ||
| Q3 24 | — | $307.7M | ||
| Q2 24 | — | $415.2M | ||
| Q1 24 | — | $380.8M |
自由现金流率CNORMD
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 31.0% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | — | 25.1% | ||
| Q2 24 | — | 33.9% | ||
| Q1 24 | — | 31.8% |
资本支出强度CNORMD
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.8% |
现金转化率CNORMD
| Q4 25 | 1.94× | 0.87× | ||
| Q3 25 | 8.56× | 1.31× | ||
| Q2 25 | 1.58× | 1.42× | ||
| Q1 25 | 9.98× | 1.59× | ||
| Q4 24 | 1.15× | 0.90× | ||
| Q3 24 | 24.86× | 1.05× | ||
| Q2 24 | 0.95× | 1.51× | ||
| Q1 24 | 0.84× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CNO
| Health Insurance Product Line | $496.4M | 43% |
| Life Insurance Segment | $268.8M | 24% |
| Other | $207.2M | 18% |
| Life And Annuity Insurance Product Line | $170.7M | 15% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
